Press Releases

Year

Sep 29, 2009

pSivida Reports Safety and Efficacy Results from 18-Month Interim Readout of Human PK Iluvien(R) Study

Sep 24, 2009

pSivida Corp. Reports Results for the Fourth Quarter and Fiscal Year Ended June 30, 2009

Sep 23, 2009

pSivida Anounces New Iluvien(R) Pilot Study in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Sep 18, 2009

pSivida CEO to Discuss New Technologies in Retinal Drug Delivery at 5th Annual Ophthalmic Drug Development and Delivery Summit

Sep 17, 2009

pSivida Corp Announces Q4 and Fiscal Year 2009 Financial Results Release Date and Conference Call Information

Sep 09, 2009

pSivida to Webcast Presentation at Rodman & Renshaw Health Care Conference

Jun 15, 2009

Two Newly-Published Scientific Papers Showed That the Steroid Used in Company's Iluvien Device Acted as Both a VEGF Inhibitor and Neuroprotectant

May 14, 2009

pSivida Corp. Reports Results for the Quarter ended March 31, 2009

Apr 24, 2009

pSivida technology featured in multiple abstracts at ARVO Meeting in Florida

Apr 09, 2009

pSivida's Iluvien Phase III Study passes final DSMB Review

Mar 30, 2009

pSivida CEO to Present at IBC Ocular Angiogenesis Conference

Mar 13, 2009

Favorable 12-Month Interim Safety and Efficacy Results from Iluvien Human PK Study

Mar 12, 2009

pSivida to Present at Cowen Health Care Conference in Boston

Mar 05, 2009

Enrollment complete in BrachySil Dose Ranging Study

Feb 12, 2009

pSivida Corp. Reports Results for the Second Quarter Ended December 31, 2008

Feb 12, 2009

pSivida 10Q for period ended Dec 31, 2008

Feb 03, 2009

Dr. Paul Ashton appointed President and CEO

Dec 17, 2008

pSivida New Evaluation for Cardiovascular Drug Delivery

Dec 12, 2008

pSivida new clinical trial for drug delivery device in AMD

Dec 03, 2008

pSivida’s BrachySil pancreatic cancer treatment featured on the BBC

Previous page
…
Page 26
Page 27
Current page 28
Page 29
Page 30
Next page

Displaying 541 - 560 of 598

News releases are posted on the Company's website as soon as possible after the release over the news wire. You should view the Financial Information section and most recent SEC Filings in the Investors section to receive the most current information made available by EyePoint Pharmaceuticals, Inc.